Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Afatinib & Non-small-cell lung cancer (NSCLC) (EGFR m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Regulatory status

In the context of Afatinib & Non-small-cell lung cancer (NSCLC) (EGFR m), afatinib is approved by both the FDA and EMA for the first-line treatment of Non-small-cell lung cancer (NSCLC) (EGFR m). The FDA granted approval in July 2013 for metastatic NSCLC patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, based on evidence from pivotal clinical trials showing improved outcomes compared to chemotherapy. EMA granted similar approval, and afatinib is recognized as a standard of care for advanced NSCLC…

References (Sources)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey et al. 2020 J Oncol Pharm Pract 26(6): 1461-1474
Review
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu et al. 2014 Lancet Oncol 15: 213-222
Duration of treatment among patients prescribed afatinib or erlotinib as 1st-line therapy for EGFR mutation-positive NSCLC in the USA
Lim et al. 2019
Efficacy and safety of afatinib for NSCLC: state-of-the-art and future perspectives
Sartori et al. 2020 Exp Rev Anticancer Therapy 20: 531-542
Review
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
Hirsh 2015 BioDrugs 29(3): 167-83
Review
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
Wang & Li 2019 Onco Targets Ther 12: 6535-6548
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
Cheng et al. 2024 BMC Cancer 24(1): 228

AI Chat

7/1/2026

Chat with our artificial intelligence: